布地格福吸入气雾剂治疗慢性阻塞性肺疾病急性加重期的疗效观察  

Effects of budesonide inhalation aerosol in the treatment of acute exacerbation of COPD

作　　者：陈秋吕 李肖 CHEN Qiulyu;LI Xiao(Department of Pharmacy,Yichun Second People's Hospital,Yichun 336000,Jiangxi,China)

机构地区：[1]宜春市第二人民医院药剂科,江西宜春336000

出　　处：《中国现代医生》2023年第9期65-68,88,共5页China Modern Doctor

摘　　要：目的探讨布地格福吸入气雾剂在慢性阻塞性肺疾病急性加重期(acute exacerbation of chronic obstructive pulmonary disease,AECOPD)患者中的应用效果。方法选取宜春市第二人民医院2021年1~10月收治的AECOPD患者70例,采用随机数字表法分为对照组和研究组,每组各35例。在常规治疗的基础上,对照组予布地奈德福莫特罗吸入粉雾剂治疗,研究组予布地格福吸入气雾剂治疗,比较两组的临床疗效、慢性阻塞性肺疾病(chronic obslructive pualmonary disease,COPD)患者自我评估测试(COPD assessment test,CAT)评分、血清学指标[C反应蛋白(C-reactive protein,CRP)、白细胞介素-6 (interleukin,IL-6)、降钙素原(procalcitonin,PCT)、基质金属蛋白酶-9 (matrix metalloproteinase,MMP-9)]及肺功能指标[肺活量(vitalcapacity,VC)、第1秒用力呼气容积(forced expiratory volume in first second,FEV_(1))、FEV_(1)占用力肺活量(forced vital capacity,FVC)比值(FEV_(1)/FVC)、呼气峰值流速(peak expiratory flow,PEF)、血气指标[动脉血氧分压(partial pressure of arterial oxygen,PaO_(2))、血二氧化碳分压(partial pressure of carbon dioxide,PaCO_(2))]、pH值和不良反应。结果治疗后,研究组患者的临床总有效率明显高于对照组(P<0.05);且研究组患者的CAT评分、CRP、IL-6、PCT、MMP-9、PaCO_(2)低于对照组(P<0.05);研究组患者的VC、FEV_(1)、FEV_(1)/FVC、PEF、PaO_(2)高于对照组(P<0.05);研究组患者的pH值高于对照组,但差异无统计学意义(P>0.05);研究组患者的不良反应发生率明显低于对照组(P<0.05)。结论使用布地格福吸入气雾剂治疗AECOPD患者可有效提高临床疗效,改善CAT评分、血清学各指标水平、血气指标及肺功能,且用药安全性较好。Objective To investigate the effect of budesonide inhalation aerosol in patients with acute exacerbation of chronic obstructive pulmonary disease(AECOPD).Methods A total of 70 patients with AECOPD in Yichun Second People's Hospital from January to October 2021 were selected and randomly divided into study group and control group,35 patients in each group.The patients were given routine treatment,the control group was treated with budesonide formoterol inhalation powder spray,and the study group was treated with budesonide inhalation aerosol,the clinical efficacy,CAT scores serological indicators[CRP,IL-6,PCT,MMP-9],pulmonary function indicators[VC,FEV_(1),FEV_(1)/FVC,PEF]and blood gas index PaO_(2),PaCO_(2),and pH,adverse reactions were compared.Results After treatment,the total clinical effective rate of patients in the study group was significantly higher than that in the control group(P<0.05).The CAT score,CRP,IL-6,PCT,MMP-9 and PaCO_(2) of patients in the study group were lower than those in the control group(P<0.05).The VC,FEV_(1),FEV_(1)/FVC,PEF and PaO_(2) of patients in the study group were higher than those in the control group(P<0.05).The pH of patients in the study group was higher than that in the control group,but the difference was not statistically significant(P>0.05).The adverse reaction rate of patients in the study group was significantly lower than that in the control group(P<0.05).Conclusion The treatment of AECOPD patients with budesonide of inhalation aerosol can effectively enhance the therapeutic effect,improve the CAT score,the level of serological indicators and pulmonary function,and the drug safety is good.

关 键 词：慢性阻塞性肺疾病急性加重期 布地格福吸入气雾剂 布地奈德福莫特罗吸入粉雾剂 CAT评分 血清学指标 肺功能 血气指标 

分 类 号：R974[医药卫生—药品]